Innoviva, Inc. (INVA)

$14.965

-0.2

(-1.29%)▲

Live

Insights on Innoviva, Inc.

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 67.25M → 89.27M (in $), with an average increase of 24.7% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, 82.04M → 61.53M (in $), with an average decrease of 25.0% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 49.7% return, outperforming this stock by 20.5%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 240.7% return, outperforming this stock by 211.1%

Performance

  • $14.95
    $15.08
    $14.97
    downward going graph

    0.13%

    Downside

    Day's Volatility :0.86%

    Upside

    0.73%

    downward going graph
  • $11.37
    $16.86
    $14.97
    downward going graph

    24.05%

    Downside

    52 Weeks Volatility :32.56%

    Upside

    11.21%

    downward going graph

Returns

PeriodInnoviva, Inc.Sector (Health Care)Index (Russel 2000)
3 Months
-8.23%
1.7%
0.0%
6 Months
19.94%
11.3%
0.0%
1 Year
29.24%
5.4%
1.3%
3 Years
28.47%
13.9%
-22.1%

Highlights

Market Capitalization
959.2M
Book Value
$10.66
Earnings Per Share (EPS)
2.2
PE Ratio
6.9
PEG Ratio
0.24
Wall Street Target Price
15.0
Profit Margin
57.89%
Operating Margin TTM
53.02%
Return On Assets TTM
7.12%
Return On Equity TTM
28.97%
Revenue TTM
310.5M
Revenue Per Share TTM
4.75
Quarterly Revenue Growth YOY
30.5%
Gross Profit TTM
276.1M
EBITDA
176.8M
Diluted Eps TTM
2.2
Quarterly Earnings Growth YOY
-0.65
EPS Estimate Current Year
0.81
EPS Estimate Next Year
0.98
EPS Estimate Current Quarter
0.23
EPS Estimate Next Quarter
0.18

Analyst Recommendation

Sell
    0
    0%Buy
    50%Hold
    50%Sell
Based on 6 Wall street analysts offering stock ratings for Innoviva, Inc.(by analysts ranked 0 to 5 stars)
Based on 6 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
00
00
00
Hold
3
3
3
Sell
3
3
3

Analyst Forecast

What analysts predicted

Upside of 0.23%

Current $14.97
Target $15.00

Company Financials

FY18Y/Y Change
Revenue
261.0M
↑ 20.16%
Net Income
395.1M
↑ 194.5%
Net Profit Margin
151.36%
↑ 89.6%
FY19Y/Y Change
Revenue
261.0M
↑ 0.0%
Net Income
157.3M
↓ 60.19%
Net Profit Margin
60.26%
↓ 91.1%
FY20Y/Y Change
Revenue
336.8M
↑ 29.03%
Net Income
224.4M
↑ 42.67%
Net Profit Margin
66.63%
↑ 6.37%
FY21Y/Y Change
Revenue
391.9M
↑ 16.35%
Net Income
265.9M
↑ 18.47%
Net Profit Margin
67.84%
↑ 1.21%
FY22Y/Y Change
Revenue
331.3M
↓ 15.45%
Net Income
213.9M
↓ 19.53%
Net Profit Margin
64.56%
↓ 3.28%
FY23Y/Y Change
Revenue
324.3M
↓ 2.14%
Net Income
179.7M
↓ 15.99%
Net Profit Margin
55.42%
↓ 9.14%
Q3 FY22Q/Q Change
Revenue
67.3M
↓ 37.85%
Net Income
265.5M
↑ 28177.21%
Net Profit Margin
394.79%
↑ 393.92%
Q4 FY22Q/Q Change
Revenue
65.8M
↓ 2.16%
Net Income
-68.3M
↓ 125.73%
Net Profit Margin
-103.82%
↓ 498.61%
Q1 FY23Q/Q Change
Revenue
76.4M
↑ 16.06%
Net Income
34.9M
↓ 151.04%
Net Profit Margin
45.65%
↑ 149.47%
Q2 FY23Q/Q Change
Revenue
81.0M
↑ 6.05%
Net Income
1.3M
↓ 96.33%
Net Profit Margin
1.58%
↓ 44.07%
Q3 FY23Q/Q Change
Revenue
67.3M
↓ 16.96%
Net Income
82.0M
↑ 6309.84%
Net Profit Margin
121.99%
↑ 120.41%
Q4 FY23Q/Q Change
Revenue
89.3M
↑ 32.73%
Net Income
61.5M
↓ 25.0%
Net Profit Margin
68.93%
↓ 53.06%
FY18Y/Y Change
Total Assets
548.2M
↑ 49.23%
Total Liabilities
389.1M
↓ 36.21%
FY19Y/Y Change
Total Assets
724.8M
↑ 32.22%
Total Liabilities
382.7M
↓ 1.65%
FY20Y/Y Change
Total Assets
999.6M
↑ 37.9%
Total Liabilities
391.7M
↑ 2.36%
FY21Y/Y Change
Total Assets
926.4M
↓ 7.32%
Total Liabilities
400.5M
↑ 2.23%
FY22Y/Y Change
Total Assets
1.2B
↑ 32.93%
Total Liabilities
665.7M
↑ 66.24%
FY23Y/Y Change
Total Assets
1.2B
↑ 0.98%
Total Liabilities
568.6M
↓ 14.59%
Q3 FY22Q/Q Change
Total Assets
1.3B
↑ 16.71%
Total Liabilities
686.3M
↑ 19.95%
Q4 FY22Q/Q Change
Total Assets
1.2B
↓ 7.25%
Total Liabilities
665.7M
↓ 3.01%
Q1 FY23Q/Q Change
Total Assets
1.1B
↓ 8.26%
Total Liabilities
568.3M
↓ 14.64%
Q2 FY23Q/Q Change
Total Assets
1.1B
↓ 1.02%
Total Liabilities
563.2M
↓ 0.9%
Q3 FY23Q/Q Change
Total Assets
1.2B
↑ 6.25%
Total Liabilities
560.6M
↓ 0.45%
Q4 FY23Q/Q Change
Total Assets
1.2B
↑ 4.66%
Total Liabilities
568.6M
↑ 1.42%
FY18Y/Y Change
Operating Cash Flow
223.5M
↑ 57.7%
Investing Cash Flow
3.5M
↓ 115.14%
Financing Cash Flow
-238.0M
↑ 45.82%
FY19Y/Y Change
Operating Cash Flow
257.5M
↑ 15.18%
Investing Cash Flow
-18.0M
↓ 611.59%
Financing Cash Flow
-23.8M
↓ 90.01%
FY20Y/Y Change
Operating Cash Flow
313.1M
↑ 21.62%
Investing Cash Flow
-314.9M
↑ 1649.36%
Financing Cash Flow
-29.8M
↑ 25.27%
FY21Y/Y Change
Operating Cash Flow
363.8M
↑ 16.19%
Investing Cash Flow
43.7M
↓ 113.88%
Financing Cash Flow
-452.5M
↑ 1419.21%
FY22Y/Y Change
Operating Cash Flow
201.7M
↓ 44.55%
Investing Cash Flow
-56.6M
↓ 229.53%
Financing Cash Flow
-55.6M
↓ 87.72%
Q3 FY22Q/Q Change
Operating Cash Flow
15.7M
↓ 80.15%
Investing Cash Flow
97.7M
↓ 3974.78%
Financing Cash Flow
-96.2M
↑ 887.81%
Q4 FY22Q/Q Change
Operating Cash Flow
8.9M
↓ 43.28%
Investing Cash Flow
-8.7M
↓ 108.88%
Financing Cash Flow
-10.0M
↓ 89.6%
Q1 FY23Q/Q Change
Operating Cash Flow
25.7M
↑ 188.62%
Investing Cash Flow
-35.7M
↑ 311.64%
Financing Cash Flow
-137.0M
↑ 1269.48%

Technicals Summary

Sell

Neutral

Buy

Innoviva, Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Innoviva, Inc.
Innoviva, Inc.
0.46%
19.94%
29.24%
28.47%
11.55%
Moderna, Inc.
Moderna, Inc.
-1.39%
41.81%
-19.31%
-38.71%
322.88%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-5.68%
13.74%
14.81%
80.88%
159.02%
Novo Nordisk A/s
Novo Nordisk A/s
-2.24%
29.49%
49.67%
240.51%
421.0%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-3.67%
10.39%
20.74%
84.71%
129.52%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Innoviva, Inc.
Innoviva, Inc.
6.9
6.9
0.24
0.81
0.29
0.07
NA
10.66
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-6.77
-0.29
-0.12
NA
36.27
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
26.13
26.13
1.46
45.02
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
48.36
48.36
2.4
3.34
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
29.17
29.17
0.53
16.75
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Innoviva, Inc.
Innoviva, Inc.
Sell
$959.2M
11.55%
6.9
57.89%
Moderna, Inc.
Moderna, Inc.
Buy
$41.3B
322.88%
24.73
-68.84%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$99.6B
159.02%
26.13
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$573.9B
421.0%
48.36
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$104.7B
129.52%
29.17
36.68%

Institutional Holdings

  • BlackRock Inc

    16.37%

  • Sarissa Capital Management LP

    11.51%

  • Vanguard Group Inc

    10.62%

  • Putnam Investments, LLC., a Franklin Templeton company

    9.92%

  • Dimensional Fund Advisors, Inc.

    7.14%

  • Renaissance Technologies Corp

    6.55%

Company Information

innoviva is focused on bringing compelling new medicines to patients in areas of unmet need by leveraging its significant expertise in the development, commercialization and financial management of bio-pharmaceuticals. innoviva's portfolio is anchored by the respiratory assets partnered with glaxo group limited (gsk), including relvar®/breo® ellipta® and anoro® ellipta®, which were jointly developed by innoviva and gsk. under the agreement with gsk, innoviva is eligible to receive associated royalty revenues from relvar®/breo® ellipta®, anoro® ellipta® and, if approved and commercialized, vi monotherapy, as well. in addition, innoviva retains a 15 percent economic interest in future payments made by gsk for earlier-stage programs partnered with theravance biopharma, inc. for more information, please visit innoviva's website at www.inva.com.

Organization
Innoviva, Inc.
Employees
112
CEO
Mr. Pavel Raifeld C.F.A.
Industry
Health Technology

Discover More

FAQs